Source-grounded facts extracted from cbdMD, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
cbdMD, Inc. entered into Asset Purchase Agreement with Gaia Botanicals, LLC valued at 425,000 shares of the Company’s restricted common stock (effective 2026-01-12).
“On January 12, 2026 (the “Closing”), cbdMD, Inc., a North Carolina corporation (the “Company”) and Gaia Botanicals, LLC, a Colorado limited liability company (“Gaia”) and Gaia’s wholly owned subsidiaries entered into an Asset Purchase Agreement (the “Agreement”).”
cbdMD, Inc.: The Company filed a Certificate of Amendment to the Certificate of Incorporation designating 1,700,000 shares of authorized preferred stock as Series B Convertible Preferred Stock (effective 2025-09-29).
“On September 29, 2025, the Company filed a Certificate of Amendment to the Certificate of Incorporation (the “Certificate of Designation”) designating 1,700,000 shares of the Company’s authorized preferred stock as Series B Convertible Preferred Stock, par value $0.001 per share.”
cbdMD, Inc. received a nyse_american noncompliance notice notice regarding stockholders equity (rules 1003(a)(i)).
“December 31, 2024, cbdMD, Inc. (the “Company”) received notification (the “Notice”) from the NYSE American LLC (the “NYSE American”) that the Company is no longer in compliance with an additional NYSE American continued”
cbdMD, Inc. shareholders approved Approval of issuance of shares upon conversion of convertible notes exceeding 19.9% of outstanding common stock at the 2024-03-29 meeting.
“Proposal 6: The approval of the issuance of shares of the Company’s common stock, representing more than 19.9% of our common stock outstanding upon the conversion of certain convertible notes issued by the Company pursuant to the Securities Purchase Agreement dated January 30, 2024 entered into by and between the Company and five institutional investors was approved, based upon the following final tabulation of votes: “For ” “Against ” “Abstain ” 906,703 14,362 4,849”
cbdMD, Inc. shareholders rejected Amendment to Certificate of Designation for Series A Preferred Stock to provide for automatic conversion into common stock at the 2024-03-29 meeting.
“Proposal 5: The approval of an amendment to the Certificate of Designation for the Series A to provide for the automatic conversion into common stock was not approved, based upon the following final tabulation of votes: Common Stock: “For ” “Against ” “Abstain ” 909,689 13,722 2,503 Series A: “For ” “Against ” “Abstain ” 1,790,169 1,674,962 -”
cbdMD, Inc. shareholders approved Advisory resolution on fiscal year 2024 compensation of named executive officers at the 2024-03-29 meeting.
“Proposal 4: The approval of an advisory resolution on the fiscal year 2024 compensation of the named executive officers was approved, based upon the following final tabulation of votes: “For ” “Against ” “Abstain ” 842,489 39,001 44,424”
cbdMD, Inc. shareholders approved Advisory vote on frequency of advisory vote on executive compensation at the 2024-03-29 meeting.
“Proposal 3: The approval of an advisory vote on the frequency of an advisory vote on executive compensation was approved, based upon the following final tabulation of votes: “One ” “Two ” “Three ” “Abstain ” 515,552 39,999 326,876 43,487”
cbdMD, Inc. shareholders approved Ratification of Cherry Bekaert LLP as independent registered public accounting firm at the 2024-03-29 meeting.
“Proposal 2: The appointment of Cherry Bekaert LLP as our independent registered public accounting firm and to audit our financial statements for the fiscal year ending September 30, 2024 was ratified, based upon the following final tabulation of votes: “For ” “Against ” “Abstain ” 1,048,934 2,071 2,904”
cbdMD, Inc. shareholders approved Election of Directors at the 2024-03-29 meeting.
“Proposal 1: The following directors were elected at the 2024 Annual Meeting of shareholders to hold office until the 2025 annual meeting of shareholders or their earlier resignation, removal or death: Directors “For ” “Against ” Bakari Sellers 894,360 31,554 William F. Raines, III 896,656 29,258 Scott G. Stephen 896,855 29,059 Dr. Sybil Swift 898,196 27,718”
Bradley Whitford was appointed as Chief Accounting Officer at cbdMD, Inc..
“Effective March 29, 2024, the Board of Directors (the "Board") of cbdMD, Inc. (the "Company") appointed Bradley Whitford, the Company's current Vice President of Finance, to serve as the Company's Chief Accounting Officer at the discretion of the Board.”
cbdMD, Inc. entered into License Agreement and Lease Forbearance Agreement with HSKL, Inc. valued at License grant and forbearance in exchange for $80,000 upfront and four monthly payments of $40,000 (effective 2024-03-14).
“Effective March 20, 2024 we entered into a License Agreement, dated as of March 14, 2024, by and between cbdMD, Inc. and HSKL, Inc. (the “License Agreement”) and Lease Forbearance Agreement, dated as of March 14, 2024, by and between cbdMD, Inc. and HSKL, Inc. (the “Forbearance Agreement”).”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.